Skip to main content

Table 5 Multivariable Cox regression model, including treatment, VEGF -1498 C/T polymorphism and their interaction as covariates

From: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Progression Free Survival

Characteristics

N

Adjusted HR

95% CI

P

Treatment

FOLFIRI

107

1

  
 

FOLFIRI + Beva

111

0.48

0.34-0.73

0.0008

Bevacizumab-Group (N = 111)

-1498

C-

82

1

  
 

T/T

29

2.97

1.28-6.59

0.011

Control Group (N = 107)

-1498

C-

80

1

  
 

T/T

27

0.71

0.38-1.27

0.235

Overall Survival

Characteristics

N

Adjusted HR

95% CI

P

Treatment

FOLFIRI

107

1

  
 

FOLFIRI + Beva

111

0.50

0.29-0.94

0.033

Bevacizumab-Group (N = 111)

-1498

C-

82

1

  
 

T/T

29

2.60

0.89-8.36

0.081

Control Group (N = 107)

-1498

C-

80

1

  
 

T/T

27

0.66

0.31-1.31

0.239

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us